Tags

Type your tag names separated by a space and hit enter

Calcium channel blocker use and risk of Parkinson's disease: a meta-analysis.
Pharmacoepidemiol Drug Saf. 2015 Jun; 24(6):559-66.PD

Abstract

PURPOSES

Whether calcium channel blocker (CCB) use contributes to a low risk of developing a first time diagnosis of Parkinson's disease (PD) remains controversial. We conducted a meta-analysis to investigate the relationship between CCB use and PD risk.

METHODS

Pubmed, EMBASE, China National Knowledge Infrastructure, and WanFang databases were searched for papers through May 2014. Studies investigating the association between CCB use and the risk of first time diagnosis of PD were included. Pooled adjusted risk ratio (RR) and 95% confidence interval (CI) were calculated using a fixed-effect model.

RESULTS

Five studies involving 208 248 CCB users were identified. Overall, CCB use was associated with a reduction in PD risk (RR = 0.76, 95%CI = 0.68-0.84) compared with the controls. Subgroup analysis showed that dihydropyridine CCB use reduced by 27% PD risk (RR = 0.73, 95%CI = 0.64-0.83) and non-dihydropyridine CCB use reduced by 30% PD risk (RR = 0.70, 95%CI = 0.50-0.93).

CONCLUSIONS

Overall, CCB use as a class is associated with a reduction in PD risk. Both of dihydropyridine and non-dihydropyridine CCB use appear to reduce the risk of developing a first time diagnosis of PD. More well-designed prospective studies are needed to investigate the difference of the subtype of CCB user on PD risk.

Authors+Show Affiliations

Institute of Molecular Biology and Translational Medicine, The Affiliated People's Hospital, Jiangsu University, Zhenjiang, 212002, Jiangsu, China.Institute of Molecular Biology and Translational Medicine, The Affiliated People's Hospital, Jiangsu University, Zhenjiang, 212002, Jiangsu, China.Institute of Molecular Biology and Translational Medicine, The Affiliated People's Hospital, Jiangsu University, Zhenjiang, 212002, Jiangsu, China.

Pub Type(s)

Journal Article
Meta-Analysis

Language

eng

PubMed ID

25845582

Citation

Lang, Yakun, et al. "Calcium Channel Blocker Use and Risk of Parkinson's Disease: a Meta-analysis." Pharmacoepidemiology and Drug Safety, vol. 24, no. 6, 2015, pp. 559-66.
Lang Y, Gong D, Fan Y. Calcium channel blocker use and risk of Parkinson's disease: a meta-analysis. Pharmacoepidemiol Drug Saf. 2015;24(6):559-66.
Lang, Y., Gong, D., & Fan, Y. (2015). Calcium channel blocker use and risk of Parkinson's disease: a meta-analysis. Pharmacoepidemiology and Drug Safety, 24(6), 559-66. https://doi.org/10.1002/pds.3781
Lang Y, Gong D, Fan Y. Calcium Channel Blocker Use and Risk of Parkinson's Disease: a Meta-analysis. Pharmacoepidemiol Drug Saf. 2015;24(6):559-66. PubMed PMID: 25845582.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Calcium channel blocker use and risk of Parkinson's disease: a meta-analysis. AU - Lang,Yakun, AU - Gong,Dandan, AU - Fan,Yu, Y1 - 2015/04/02/ PY - 2014/08/12/received PY - 2015/01/17/revised PY - 2015/03/13/accepted PY - 2015/4/8/entrez PY - 2015/4/8/pubmed PY - 2016/2/24/medline KW - Parkinson's disease KW - calcium channel blockers KW - dihydropyridine KW - meta-analysis KW - pharmacoepidemiology SP - 559 EP - 66 JF - Pharmacoepidemiology and drug safety JO - Pharmacoepidemiol Drug Saf VL - 24 IS - 6 N2 - PURPOSES: Whether calcium channel blocker (CCB) use contributes to a low risk of developing a first time diagnosis of Parkinson's disease (PD) remains controversial. We conducted a meta-analysis to investigate the relationship between CCB use and PD risk. METHODS: Pubmed, EMBASE, China National Knowledge Infrastructure, and WanFang databases were searched for papers through May 2014. Studies investigating the association between CCB use and the risk of first time diagnosis of PD were included. Pooled adjusted risk ratio (RR) and 95% confidence interval (CI) were calculated using a fixed-effect model. RESULTS: Five studies involving 208 248 CCB users were identified. Overall, CCB use was associated with a reduction in PD risk (RR = 0.76, 95%CI = 0.68-0.84) compared with the controls. Subgroup analysis showed that dihydropyridine CCB use reduced by 27% PD risk (RR = 0.73, 95%CI = 0.64-0.83) and non-dihydropyridine CCB use reduced by 30% PD risk (RR = 0.70, 95%CI = 0.50-0.93). CONCLUSIONS: Overall, CCB use as a class is associated with a reduction in PD risk. Both of dihydropyridine and non-dihydropyridine CCB use appear to reduce the risk of developing a first time diagnosis of PD. More well-designed prospective studies are needed to investigate the difference of the subtype of CCB user on PD risk. SN - 1099-1557 UR - https://www.unboundmedicine.com/medline/citation/25845582/Calcium_channel_blocker_use_and_risk_of_Parkinson's_disease:_a_meta_analysis_ L2 - https://doi.org/10.1002/pds.3781 DB - PRIME DP - Unbound Medicine ER -